B-Cell Maturation Antigen: A member of the tumor necrosis factor receptor superfamily found on mature B-LYMPHOCYTES. It has specificity for B CELL ACTIVATING FACTOR and TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Tumor Necrosis Factor Ligand Superfamily Member 13: A member of tumor necrosis factor superfamily found on MACROPHAGES; DENDRITIC CELLS and T-LYMPHOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; and B CELL MATURATION ANTIGEN.Transmembrane Activator and CAML Interactor Protein: A tumor necrosis factor receptor superfamily member found expressed on peripheral B-LYMPHOCYTES. It has specificity for B-CELL MATURATION ANTIGEN and TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13.B-Cell Activating Factor: A tumor necrosis factor superfamily member that plays a role in the regulation of B-LYMPHOCYTE survival. It occurs as a membrane-bound protein that is cleaved to release an biologically active soluble form with specificity to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; B-CELL ACTIVATION FACTOR RECEPTOR; and B-CELL MATURATION ANTIGEN.B-Cell Activation Factor Receptor: A member of the tumor necrosis factor receptor superfamily that specifically binds B-CELL ACTIVATING FACTOR. It is found on B-LYMPHOCYTES and plays a role in maturation and survival of B-cells. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Receptors, Tumor Necrosis Factor: Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.B-Lymphocyte Subsets: A classification of B-lymphocytes based on structurally or functionally different populations of cells.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Antigens: Substances that are recognized by the immune system and induce an immune reaction.Receptors, Antigen, B-Cell: IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.Lymphocyte Activation: Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.Precursor Cells, B-Lymphoid: Lymphocyte progenitor cells that are restricted in their differentiation potential to the B lymphocyte lineage. The pro-B cell stage of B lymphocyte development precedes the pre-B cell stage.Spleen: An encapsulated lymphatic organ through which venous blood filters.Mice, Inbred C57BLAntigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Germinal Center: The activated center of a lymphoid follicle in secondary lymphoid tissue where B-LYMPHOCYTES are stimulated by antigens and helper T cells (T-LYMPHOCYTES, HELPER-INDUCER) are stimulated to generate memory cells.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.Immunoglobulin D: An immunoglobulin which accounts for less than 1% of plasma immunoglobulin. It is found on the membrane of many circulating B LYMPHOCYTES.Lentivirus: A genus of the family RETROVIRIDAE consisting of non-oncogenic retroviruses that produce multi-organ diseases characterized by long incubation periods and persistent infection. Lentiviruses are unique in that they contain open reading frames (ORFs) between the pol and env genes and in the 3' env region. Five serogroups are recognized, reflecting the mammalian hosts with which they are associated. HIV-1 is the type species.Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.Boronic Acids: Inorganic or organic compounds that contain the basic structure RB(OH)2.PyrazinesTreatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Receptors, Tumor Necrosis Factor, Type I: A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.Receptors, Tumor Necrosis Factor, Member 6b: A secreted tumor necrosis factor receptor family member that has specificity FAS LIGAND and TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14. It plays a modulating role in tumor necrosis factor signaling pathway.Antigens, CD137: A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Tumor Necrosis Factor-alpha: Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.PubMed: A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.BooksPublishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.MEDLINE: The premier bibliographic database of the NATIONAL LIBRARY OF MEDICINE. MEDLINE® (MEDLARS Online) is the primary subset of PUBMED and can be searched on NLM's Web site in PubMed or the NLM Gateway. MEDLINE references are indexed with MEDICAL SUBJECT HEADINGS (MeSH).Fushi Tarazu Transcription Factors: Fushi tarazu transcription factors were originally identified in DROSOPHILA. They are found throughout ARTHROPODS and play important roles in segmentation and CENTRAL NERVOUS SYSTEM development.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Databases, Genetic: Databases devoted to knowledge about specific genes and gene products.Genome, Human: The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs.Dictionaries, MedicalTumor Necrosis Factor Ligand Superfamily Member 15: A member of tumor necrosis factor superfamily found on ENDOTHELIAL CELLS that plays a role in the inhibition of endothelial cell growth and PHYSIOLOGIC ANGIOGENESIS.Tumor Necrosis Factor Ligand Superfamily Member 14: A member of tumor necrosis factor superfamily found on activated LYMPHOCYTES and MONOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to LYMPHOTOXIN BETA RECEPTOR and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14.Tumor Necrosis Factors: A family of proteins that were originally identified by their ability to cause NECROSIS of NEOPLASMS. Their necrotic effect on cells is mediated through TUMOR NECROSIS FACTOR RECEPTORS which induce APOPTOSIS.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Ligands: A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)Recombinant Proteins: Proteins prepared by recombinant DNA technology.Astragalus membranaceus: A plant species of the Astragalus genus which is source of Huang qi preparation used in TRADITIONAL CHINESE MEDICINE.Interleukin-6: A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.

BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. (1/82)

The tumor necrosis factor (TNF) family member B cell activating factor (BAFF) binds B cells and enhances B cell receptor-triggered proliferation. We find that B cell maturation antigen (BCMA), a predicted member of the TNF receptor family expressed primarily in mature B cells, is a receptor for BAFF. Although BCMA was previously localized to the Golgi apparatus, BCMA was found to be expressed on the surface of transfected cells and tonsillar B cells. A soluble form of BCMA, which inhibited the binding of BAFF to a B cell line, induced a dramatic decrease in the number of peripheral B cells when administered in vivo. Moreover, culturing splenic cells in the presence of BAFF increased survival of a percentage of the B cells. These results are consistent with a role for BAFF in maintaining homeostasis of the B cell population.  (+info)

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. (2/82)

BLyS (also called TALL-1, THANK, or BAFF) [1] [2] [3] [4] is a member of the tumor necrosis factor (TNF) gene family that stimulates proliferation and immunoglobulin production by B cells. BLyS interacts with the TNF receptor (TNFR) homologue TACI (transmembrane activator and CAML-interactor) [5], and treatment of mice with a TACI-Fc fusion protein abolishes germinal center formation after antigenic challenge [6]. Here we report a novel interaction between BLyS and another TNFR homologue, BCMA (B cell maturation antigen) [7] [8]. Further, the TNF homologue APRIL [9], a close relative of BLyS, also bound to BCMA and TACI. BLyS or APRIL activated nuclear factor-kappaB (NF-kappaB) through TACI and BCMA, and each ligand stimulated immunoglobulin M (IgM) production by peripheral blood B cells. These results define a dual ligand-receptor system that may play an important role in humoral immunity.  (+info)

TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. (3/82)

BCMA (B cell maturation) is a nonglycosylated integral membrane type I protein that is preferentially expressed in mature B lymphocytes. Previously, we reported in a human malignant myeloma cell line that BCMA is not primarily present on the cell surface but lies in a perinuclear structure that partially overlaps the Golgi apparatus. We now show that in transiently or stably transfected cells, BCMA is located on the cell surface, as well as in a perinulear Golgi-like structure. We also show that overexpression of BCMA in 293 cells activates NF-kappa B, Elk-1, the c-Jun N-terminal kinase, and the p38 mitogen-activated protein kinase. Coimmunoprecipitation experiments performed in transfected cells showed that BCMA associates with TNFR-associated factor (TRAF) 1, TRAF2, and TRAF3 adaptor proteins. Analysis of deletion mutants of the intracytoplasmic tail of BCMA showed that the 25-aa protein segment, from position 119 to 143, conserved between mouse and human BCMA, is essential for its association with the TRAFs and the activation of NF-kappa B, Elk-1, and c-Jun N-terminal kinase. BCMA belongs structurally to the TNFR family. Its unique TNFR motif corresponds to a variant motif present in the fourth repeat of the TNFRI molecule. This study confirms that BCMA is a functional member of the TNFR superfamily. Furthermore, as BCMA is lacking a "death domain" and its overexpression activates NF-kappa B and c-Jun N-terminal kinase, we can reasonably hypothesize that upon binding of its corresponding ligand BCMA transduces signals for cell survival and proliferation.  (+info)

B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. (4/82)

TALL-1 is a recently identified member of the tumor necrosis factor (TNF) family that costimulates B lymphocyte proliferation. Here we show that B cell maturation protein (BCMA), a member of the TNF receptor family that is expressed only by B lymphocytes, specifically binds to TALL-1. A soluble receptor containing the extracellular domain of BCMA blocks the binding of TALL-1 to its receptor on the plasma membrane and inhibits TALL-1-triggered B lymphocyte costimulation. Overexpression of BCMA activates NF-kappaB, and this activation is potentiated by TALL-1. Moreover, BCMA-mediated NF-kappaB activation is inhibited by dominant negative mutants of TNF receptor-associated factor 5 (TRAF5), TRAF6, NF-kappaB-inducing kinase (NIK), and IkappaB kinase (IKK). These data indicate that BCMA is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of BCMA as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases.  (+info)

A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. (5/82)

A proliferation-inducing ligand (APRIL) is a ligand of the tumor necrosis factor (TNF) family that stimulates tumor cell growth in vitro and in vivo. Expression of APRIL is highly upregulated in many tumors including colon and prostate carcinomas. Here we identify B cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand (CAML) interactor (TACI), two predicted members of the TNF receptor family, as receptors for APRIL. APRIL binds BCMA with higher affinity than TACI. A soluble form of BCMA, which inhibits the proliferative activity of APRIL in vitro, decreases tumor cell proliferation in nude mice. Growth of HT29 colon carcinoma cells is blocked when mice are treated once per week with the soluble receptor. These results suggest an important role for APRIL in tumorigenesis and point towards a novel anticancer strategy.  (+info)

B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. (6/82)

B-cell maturation protein (BCMA) is a member of the tumor necrosis factor (TNF) receptor family and is expressed in B lymphocytes. BCMA binds two TNF family members, BAFF and APRIL, that stimulate cellular proliferation. BAFF in particular has been shown to influence B-cell survival and activation, and transgenic mice overexpressing BAFF have a lupus-like autoimmune disorder. We have inactivated BCMA in the mouse germ line. BCMA(-/-) mice have normal B-cell development, and the life span of mutant B lymphocytes is comparable to that of wild-type B cells. The humoral immune responses of BCMA(-/-) mice to T-cell-independent antigens as well as high and low doses of T-cell-dependent antigens are also intact. In addition, mutant mice have normal splenic architecture, and germinal centers are formed during an ongoing immune response. These data suggest a functional redundancy of BCMA in B-cell physiology that is probably due to the presence of TACI, another TNF receptor family member that is expressed on B cells and that can also bind BAFF and APRIL.  (+info)

An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. (7/82)

The B cell activating factor BAFF (BlyS/TALL-1/zTNF4) is a tumor necrosis factor (TNF)-related ligand that promotes B cell survival and binds to three receptors (BCMA, TACI, and the recently described BAFF-R). Here we report an absolute requirement for BAFF in normal B cell development. Examination of secondary lymphoid organs from BAFF-deficient mice revealed an almost complete loss of follicular and marginal zone B lymphocytes. In contrast, mice lacking BCMA had normal-appearing B lymphocyte compartments. BAFF therefore plays a crucial role in B cell development and can function through receptors other than BCMA.  (+info)

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. (8/82)

B cell homeostasis has been shown to critically depend on BAFF, the B cell activation factor from the tumor necrosis factor (TNF) family. Although BAFF is already known to bind two receptors, BCMA and TACI, we have identified a third receptor for BAFF that we have termed BAFF-R. BAFF-R binding appears to be highly specific for BAFF, suggesting a unique role for this ligand-receptor interaction. Consistent with this, the BAFF-R locus is disrupted in A/WySnJ mice, which display a B cell phenotype qualitatively similar to that of the BAFF-deficient mice. Thus, BAFF-R appears to be the principal receptor for BAFF-mediated mature B cell survival.  (+info)

*B-cell maturation antigen

... (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a ... Shu HB, Johnson H (Aug 2000). "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1". ... Shu HB, Johnson H (Aug 2000). "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1". ... TNFRSF17 is a cell surface receptor of the TNF receptor superfamily which recognizes B-cell activating factor (BAFF). The ...

*List of human clusters of differentiation

"Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma - Full Text View - ClinicalTrials. ... "hcdm, Human Cell Differentiation Molecules". www.hcdm.org. Retrieved 2015-10-15. "hcdm, Human Cell Differentiation Molecules". ... "hcdm, Human Cell Differentiation Molecules". www.hcdm.org. Retrieved 2015-10-15. "hcdm, Human Cell Differentiation Molecules". ... "hcdm, Human Cell Differentiation Molecules". www.hcdm.org. Retrieved 2015-10-13. "hcdm, Human Cell Differentiation Molecules". ...

*Monomethyl auristatin F

"Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent ... It is linked to an antibody with high affinity to structures on cancer cells, causing MMAF to accumulate in such cells. MMAF is ... Monomethyl auristatin F is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin. ...

*BAFF receptor

B-cell maturation antigen GRCh38: Ensembl release 89: ENSG00000159958 - Ensembl, May 2017 GRCm38: Ensembl release 89: ... B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. The ... Rolink AG, Melchers F (Apr 2002). "BAFFled B cells survive and thrive: roles of BAFF in B-cell development". Current Opinion in ... "BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells". ...

*Fasciola hepatica

"The Fasciola hepatica Tegumental Antigen Suppresses Dendritic Cell Maturation and Function". Infection and Immunity. 77 (6): ... These cells are modified parenchyme cells. In F. hepatica, their role is to perform excretion, but more importantly, ... This means it is made from the fusion of many cells, each containing one nucleus, to produce a multinucleated cell membrane. In ... Instead, the nuclei are found in the cell bodies, also known as tegumental cells, these connect to the outer cytoplasm via thin ...

*FOXN1

In thymic epithelial cells, FOXN1 has been shown to bind to and regulate genes involved in T-cell maturation and antigen ... "Dedicated epithelial recipient cells determine pigmentation patterns". Cell. 130 (5): 932-42. doi:10.1016/j.cell.2007.07.024. ... "Foxn1 regulates key target genes essential for T cell development in postnatal thymic epithelial cells". Nature Immunology. 17 ... A mutation in this gene has been correlated with T-cell immunodeficiency, the skin disorder congenital alopecia, and nail ...

*Juno Therapeutics

... fully human binding domain targeting B-cell maturation antigen. In January 2018, Celgene announced it would acquire Juno for $9 ... In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product ... The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates. In ... allowing it to use next-generation single cell sequencing platforms to complement its ability to create T cells engineered to ...

*Belimumab

BAFF interacts with three membrane receptors on B lymphocytes: BAFF-R (BAFF receptor) BCMA (B cell maturation antigen) TACI ( ... B lymphocytes (B cells) are one of the immune cells responsible for the damage in autoimmune disease. B cells develop in the ... When autoimmune B cells attack the body's own tissues, they are normally destroyed by cell suicide (apoptosis). In order to ... Researchers theorize that SLE is caused when autoimmune B cells proliferate, and survival factors protect them from cell ...

*BCMA

... a barcode system designed to prevent medication errors in healthcare settings B-cell maturation antigen, a protein that in ...

*B-cell activating factor

B-cell maturation antigen), all of which have differing binding affinities for it. These receptors are expressed mainly on ... This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an ... Shu HB, Johnson H (August 2000). "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1". ... Shu HB, Johnson H (August 2000). "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1". ...

*Clinical uses of mesenchymal stem cells

MSCs can also produce an immunomodulating effect by stimulating the maturation of antigen presenting cells. Antigen presenting ... Mesenchymal stem cells have the capacity to become any type of fully developed cell, which can contribute to replacing muscle ... The neural stem cells can then promote the repair of damaged axons and create replacement cells for the damaged tissue. ... The kind of mature, fully differentiated cell phenotype and the number of those cells created though this can be influenced in ...

*X-linked severe combined immunodeficiency

... of excised DNA fragments which are generated during normal splicing of T-cell surface antigen receptors and T-cell maturation. ... B cells, natural killer cells, glial cells, and cells of the monocyte lineage, depending on the cell type and receptor ... is an immunodeficiency disorder in which the body produces very few T cells and NK cells. In the absence of T cell help, B ... Because these cells never receive these signals, they can never mature and differentiate into full grown immune cells. ...

*CD83

"Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific ... "A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes ... "CD83 on dendritic cells: more than just a marker for maturation". Trends Immunol. 23 (6): 273-5. doi:10.1016/S1471-4906(02) ... "Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation ...

*Thymic stromal lymphopoietin

It is known to play an important role in the maturation of T cell populations through activation of antigen presenting cells. ... stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells ... dendritic cells. TSLP has also been shown to activate the maturation of a specific subset of dendritic cells located within the ... epithelial cells and different types of stromal or stromal-like cells.[citation needed] These cells are located in regions ...

*Federica Sallusto

Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opinion ... Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266. Ghia P, Transidico P, ... MHC biosynthesis and degradation optimizes presentation of infectious antigens in maturing dendritic cells. In: Dendritic Cells ... Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol 2000, 30:2394-2403. ...

*Beta-2 microglobulin

Krangel MS, Orr HT, Strominger JL (1980). "Assembly and maturation of HLA-A and HLA-B antigens in vivo". Cell. 18 (4): 979-91. ... In the absence of MHC class I, CD8 T cells cannot develop. (CD8 T cells are a subset of T cells involved in the development of ... 1993). "Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2- ... deficient in the expression of HLA class I antigens on the cell surface". Cancer Res. 52 (5): 1201-4. PMID 1737380. Saper MA, ...

*C-C chemokine receptor type 6

This receptor has been shown to be important for B-lineage maturation and antigen-driven B-cell differentiation, and it may ... 1997). "A somatic cell hybrid panel for distal 17q: GDIA1 maps to 17q25.3". Cytogenet. Cell Genet. 76 (3-4): 172-5. doi:10.1159 ... The gene is preferentially expressed by immature dendritic cells and memory T cells. The ligand of this receptor is macrophage ... 2002). "CCR6 colocalizes with CD18 and enhances adhesion to activated endothelial cells in CCR6-transduced Jurkat T cells". J. ...

*Sjögren syndrome antigen B

"Control of transfer RNA maturation by phosphorylation of the human La antigen on serine 366". Molecular Cell. 6 (2): 339-48. ... Helsloot J, Sturgess A (December 1997). "T cell reactivity to Sjögren's syndrome related antigen La(SSB)". The Journal of ... Sjögren syndrome type B antigen (SS-B) also known as Lupus La protein is a protein that in humans is encoded by the SSB gene. ... Sjögren syndrome antigen B has been shown to interact with nucleolin. La domain GRCh38: Ensembl release 89: ENSG00000138385 - ...

*Antigen-presenting cell

... affinity maturation, as well as formation of memory cells. Non-professional antigen presenting cells include all nucleated cell ... B cells can internalize antigen that binds to their B cell receptor and present it to helper T cells. Unlike T cells, B cells ... B cells and dendritic cells, present foreign antigens to helper T cells, while other cell types can present antigens ... An antigen-presenting cell (APC) or accessory cell is a cell that displays antigen complexed with major histocompatibility ...

*Coley's toxins

... lead to activation and maturation of tumor-antigen loaded dendritic cells. One PAMP thought to play a major role is the ... where physical damage to cancer cells leads to a sudden supply of cancer antigens to the dendritic cell population. Recently ( ... which activate resting dendritic cells (DC), leading to the activation of anergic T cells, possibly accomplished through a ...

*Protein THEMIS

The protein functions through T-cell antigen receptor signaling, and is necessary for proper lineage commitment and maturation ... "Themis controls thymocyte selection through regulation of T cell antigen receptor-mediated signaling". Nat. Immunol. 10 (8): ... This protein plays a regulatory role in both positive and negative T cell selection during late thymocyte development. ... a T cell-specific protein important for late thymocyte development". Nat. Immunol. 10 (8): 840-7. doi:10.1038/ni.1768. PMC ...

*Receptor editing

During maturation in the bone marrow, B cells are tested for interaction with self antigens, which is called negative selection ... Receptor editing is a process that occurs during the maturation of B cells, which are part of the adaptive immune system. This ... If the maturing B cells strongly interact with these self antigens, they undergo death by apoptosis. Negative selection is ... Halverson R, Torres RM, Pelanda R (2004). "Receptor editing is the main mechanism of B cell tolerance toward membrane antigens ...

*Cross-presentation

The action of cross priming can bolster immunity against antigens that target dendritic cells in order to inhibit maturation ... This resulted in CD8 T cell responses that were induced by antigen-presenting cells of the recipient, implying that these must ... Antigen-presenting cells capable of cross-presentation are primarily dendritic cells, but macrophages, B lymphocytes and ... Cross-presentation is the ability of certain antigen-presenting cells to take up, process and present extracellular antigens ...

*Antigen presentation

Flores-Romo, Leopoldo (2017-01-04). "In vivo maturation and migration of dendritic cells". Immunology. 102 (3): 255-262. doi: ... Because T cells recognise only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen ... Antigens generated endogenously within these cells are bound to MHC-I molecules and presented on the cell surface. This antigen ... B-cell receptors on the surface of B cells bind to intact native and undigested antigens of structural nature, rather than to a ...

*B cell

... have antibodies with a higher affinity towards their target antigen due to affinity maturation in the germinal center (GC) and ... Antigens that activate B cells with the help of T-cell are known as T cell-dependent (TD) antigens and include foreign proteins ... At the SLO, B cell activation begins when the B cell binds to an antigen via its BCR. Of the three B cell subsets, FO B cells ... Antigens that activate B cells without T cell help are known as T cell-independent (TI) antigens and include foreign ...

*Phage display

Instead, one could cleave in a section between the bead and the antigen to elute. Since the pIII is intact it does not matter ... The use of a helper phage can be eliminated by using 'bacterial packaging cell line' technology. Elution can be done combining ... "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range". J. Mol. ... Then the expression of single chain Fv's (scFv), and single chain T cell receptors (scTCR) were expressed both with and without ...
Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM). This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m2. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 × 106 cells/kg [range, 0.07 to 2.1 × 106]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group. At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were reported
During this years annual meeting, Seattle Genetics and Unum Therapeutics presented pre-clinical data evaluating combination treatment with Antibody-Coupled T cell Receptor (ACTR) engineered autologous T cells and an antibody targeting B-cell maturation antigen or BCMA.. The ACTR technology enables the programming of a patients immune system to attack tumor cells when co-administered with tumor-specific therapeutic antibodies. The pre-clinical data support clinical evaluation of a humanized non-fucosylated anti-BCMA antibody, known as SEA-BCMA, being developed using Seattle Genetics novel sugar-engineered antibody (SEA) technology, and ACTR T cell combination treatment in multiple myeloma patients.. Designed to engage the Fc domain of therapeutic antibodies, the ACTR technology, is a universal, engineered T cell therapy consisting of the extracellular domain of human CD16 and the intracellular T cell co-stimulatory and signal domain.. One presentation highlighted data from pre-clincal studies ...
Acronyms and Abbreviations: ALL, acute lymphatic leukemia; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; cDNA, complementary DNA; CDR3, complementarity determining region 3; CEA, carcinoembryonic antigen; CLL, chronic lymphatic leukemia; CMV, cytomegalovirus; CRS, cytokine release syndrome; CTL, cytotoxic T lymphocyte; DLI, donor lymphocyte infusion; E, early viral protein; EBV, Epstein-Barr virus; EGFR, epidermal growth factor receptor; ERBB2IP, erbb2 interacting protein; GD2, disialoganglioside; GVHD, graft-versus-host disease; GVL, graft-versus-leukemia; HHV-6, human herpes virus-6; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex virus; HSV-TK, herpes simplex virus thymidine kinase; iCasp9, inducible caspase-9; IE, immediate early viral protein; IFN-γ, interferon-γ; IL, interleukin; L1CAM, L1-cell adhesion molecule; LCL, lymphoblastoid cell line; LPD, lymphoproliferative disease; mAbs, monoclonal antibodies; mHAgs, minor ...
Update-1 BLUE Drops 1.96% and 1.77% After Hours 6/3 In the bubbly CAR-T world bluebird bio (BLUE) and Celgene announced a deal for for development of product candidates for B-cell maturation antigen (BMCA) utilizing bluebird bioss gene therapy technology to modify a patients own T-Cells to target cancer cells. A $25M up-front payment was made but […]. ...
BACKGROUND. CAR T cells are a promising therapy for hematologic malignancies. B cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM). METHODS. We conducted a phase I study of autologous T cells lentivirally transduced with a fully human, BCMA-specific CAR containing CD3ζ and 4-1BB signaling domains (CART-BCMA), in subjects with relapsed/refractory MM. Twenty-five subjects were treated in 3 cohorts as follows: cohort 1, 1 × 108 to 5 × 108 CART-BCMA cells alone; cohort 2, cyclophosphamide (Cy) 1.5 g/m2 plus 1 × 107 to 5 × 107 CART-BCMA cells; cohort 3, Cy 1.5 g/m2 plus 1 × 108 to 5 × 108 CART-BCMA cells. No prespecified BCMA expression level was required. RESULTS. CART-BCMA cells were manufactured and expanded in all subjects. Toxicities included cytokine release syndrome and neurotoxicity, which were grade 3-4 in 8 (32%) and 3 (12%) subjects, respectively, and reversible. One subject died at day 24 from candidemia and progressive myeloma, following treatment for ...
BACKGROUND. CAR T cells are a promising therapy for hematologic malignancies. B cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM). METHODS. We conducted a phase I study of autologous T cells lentivirally transduced with a fully human, BCMA-specific CAR containing CD3ζ and 4-1BB signaling domains (CART-BCMA), in subjects with relapsed/refractory MM. Twenty-five subjects were treated in 3 cohorts as follows: cohort 1, 1 × 108 to 5 × 108 CART-BCMA cells alone; cohort 2, cyclophosphamide (Cy) 1.5 g/m2 plus 1 × 107 to 5 × 107 CART-BCMA cells; cohort 3, Cy 1.5 g/m2 plus 1 × 108 to 5 × 108 CART-BCMA cells. No prespecified BCMA expression level was required. RESULTS. CART-BCMA cells were manufactured and expanded in all subjects. Toxicities included cytokine release syndrome and neurotoxicity, which were grade 3-4 in 8 (32%) and 3 (12%) subjects, respectively, and reversible. One subject died at day 24 from candidemia and progressive myeloma, following treatment for ...
Buy our Recombinant Mouse BCMA protein. Ab109162 is a protein fragment produced in HEK 293 cells and has been validated in FuncS, SDS-PAGE. Abcam provides free…
购买我们的重组人BCMA蛋白。Ab50089为蛋白片段,在大肠杆菌中生产并经过SDS-PAGE实验验证。Abcam提供免费的实验方案,操作技巧及专业的支持。中国80%以上现货。
If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team ...
The samples used in this paper were obtained from patients with osteoarthritis (OA) or RA during knee-TEP operations. First of all, expression of the known BAFF-binding receptors BCMA, TACI and BAFF-R was analyzed in SF of patients with OA and RA using flow cytometry and immunohistochemistry. In a further step, the influence of several stimulants, including cytokines, TLR-agonists and cell activators on receptor expression was tested. Finally, taking into account BAFF function in other cell types, SF were stimulated with BAFF and stained with Annexin V in order to analyze its effect on apoptosis in SF ...
我就喜欢看着你们发神经3 到处乱跑3不要太拘束嘛》 很开心3你们走过来和我聊天》 说班上的男生好幼稚3哈哈哈哈( 童年嘛3两样东西别少了》 1(真 2(傻 是的3谁没傻过3 谁没犯过错》 别急着呈现完美3 世界并不完美3 完美是一种包装》 包装很重要( 不过3晚一点再学吧》 包装 ...
Translation of caries | The most common chronic disease of childhood is early childhood caries (dental caries in children younger than six years
A Tumor Necrosis Factor superfamily member that plays a Role in the Regulation of B-Lymphocyte Survival. It occurs as a Membrane-bound protein that is cleaved to release an biologically active soluble form with specificity to Transmembrane Activator and CAML Interactor Protein; B-Cell Activation Factor Receptor; and B-Cell Maturation Antigen ...
Complete information for FAF2 gene (Protein Coding), Fas Associated Factor Family Member 2, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium
Background The TNF superfamily member B lymphocyte stimulator (BLyS), referred to as BAFF, is known to be an effective modulator of peripheral B cell homeostasis that promotes B cell survival and differentiation. BLyS is expressed by a few stromal cells, T cells, and most myeloid cell. BLyS transgenic mice show an expansion of the peripheral mature B cell compartment, hyperglobulinemia, anti-single-stranded DNA and anti-double-stranded DNA antibodies, and circulating immune complexes. A proliferation-inducing ligand (APRIL) is a homolog to BLyS that is expressed by monocytes, macrophages, DCs, T cells, and others. APRIL is virtually undetectable in normal tissues but is strongly expressed in adenocarcinomas and can accelerate the growth of malignant cells in vitro and in vivo. APRIL/BLyS heterotrimers are present in the serum of patients with systemic autoimmune diseases like rheumatoid arthritis (RA), SLE, and SS. APRIL over expression promotes a strong survival signal for both CD4+ and CD8+ T ...
Toda la información sobre las últimas publicaciones científicas de la Clínica Universidad de Navarra. Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer
Naive peripheral B cells survive in vivo because of active stimulation by the TNF superfamily ligand B lymphocyte stimulator (BLyS/BAFF). Although the survival promoting properties of BLyS are well known, the signal pathways and molecular effectors that characterize this stimulation are still being elucidated. In this communication, we discuss the signal cascades that effect BLyS dependent survival and the regulation of BLyS induced signaling. We also examine the role of BLyS as a growth factor and propose that BLyS induced metabolic enhancement optimizes the B cell response to BCR and TLR-dependent signaling.
The principle role of the company is to identify, to verify the validity and ultimately to offer a range of biochemical assays each of which will provide unique and informative results to the condition of an individual patient from which the physician can
There are comments on PubPeer for publication: Talin1 is required for integrin-dependent B lymphocyte homing to lymph nodes and the bone marrow but not for follicular B-cell maturation in the spleen (2010)
A Proliferation Inducing Ligand (APRIL) is a TNF ligand that, via its receptors TACI and BCMA, is involved in both B cell physiology as well as in proliferation and survival of malignant B cells. To target APRIL-dependent stimulation of B cell cancers, we recently produced and characterized two monoclonal antagonistic anti-human APRIL antibodies called humanAPRIL.01A (hA.01A) and humanAPRIL.03A (hA.03A). In a first biochemical assay to validate their blocking activity, hA.01A was shown to fully prevent APRIL from binding to its receptors, whereas a substantial difference was detected for hA.03A, which inhibited APRIL binding to BCMA less efficiently than hA.01A. Epitope mapping subsequently revealed that hA.01A and hA.03A bind distinct sites on APRIL, which provided a structural rationale of their different blocking activities. Importantly, this differential inhibition profile can be used to functionally dissect BCMA and TACI-dependent signals and indicated that B cell survival and IgA ...
Είναι το τελευταίο ποίημα του Σεφέρη και δημοσιεύτηκε στο Βήμα (23.9.71) τρεις μέρες μετά το θάνατό του στην περίοδο της δικτατορίας. Το ποίημα βασίζεται σε μια περικοπή του Πλάτωνα (Πολιτεία 614 κ.ε.) που αναφέρεται στη μεταθανάτια τιμωρία των αδίκων και ιδιαίτερα του Αρδιαίου. Ο Αρδιαίος, τύραννος σε μια πόλη, είχε σκοτώσει τον πατέρα του και τον μεγαλύτερο του αδερφό του. Γι αυτό και η τιμωρία του, καθώς και των άλλων τυράννων, στον άλλο κόσμο στάθηκε φοβερή. Όταν εξέτισαν την καθιερωμένη ποινή που επιβαλλόταν στους αδίκους και ετοιμαζόταν να βγουν στο ...
Tumor Necrosis Factor Ligand Superfamily Member 13: A member of tumor necrosis factor superfamily found on MACROPHAGES; DENDRITIC CELLS and T-LYMPHOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; and B CELL MATURATION ANTIGEN.
B cell-activating factor belonging to the TNF family (BAFF) and its receptor BAFF-R play critical roles in the maturation and survival of conventional peripheral B cells. However, they appeared to be dispensable for the generation and maintenance of CD5(+) B-1 cells as BAFF(-/-) and BAFF-R(-/-) mice have normal B-1 cell populations. Hence, it is presently unclear if B-1 cells are responsive to BAFF and if BAFF regulates some aspects of B-1 cell function. We show here that BAFF-R and transmembrane activator and CAML interactor (TACI) are the major receptors expressed by B-1 cells. Specifically, we show that BAFF treatment of B-1 cells leads to increased NF-kappaB p100 processing and CD21/CD35 expression. Interestingly, toll-like receptor (TLR) engagement of B-1 cells augmented the surface expression of BAFF receptors and rendered them responsive to BAFF costimulation, as evidenced by their increased proliferation, expression of cell surface activation markers and secretion of the pro-inflammatory
BAFF大鼠单克隆抗体[Buffy 2](ab16081)可与小鼠, 人样本反应并经WB, IHC, Flow Cyt实验严格验证,被13篇文献引用。所有产品均提供质保服务,中国75%以上现货。
Gentaur molecular products has all kinds of products like :search , Kamiya \ BAFF, FTIC labeled Clone Buffy_2 \ MC-109 for more molecular products just contact us
Arrow Chemical is a world famous chemical supplier. With the goal of customer satisfaction, Arrow focuses on Propylene Carbonate, Propylene Glycol, Dimethyl Carbonate, Methylene Chloride, Aniline, Polyaluminium Chloride, Polyacrylamide and other chemical products production, research, marketing and investment, to provide chemical purchasing one-stop service for the whole industry chain.
Looking for online definition of heat-shock transcription factor family member 5 in the Medical Dictionary? heat-shock transcription factor family member 5 explanation free. What is heat-shock transcription factor family member 5? Meaning of heat-shock transcription factor family member 5 medical term. What does heat-shock transcription factor family member 5 mean?
Results The mean disease duration of SLE was 7,0 [2,0-10,0] years, SLEDAI 2K score - 4 [2-13], SLICC damage index score - 0 [0-1], current prednisone dose - 10,0 [7,5-25,0] mg/day. SLE pts did not differ from healthy controls in BAFF (0,02 [0,02-0,08] vs 0,02 [0,02-0,02] ng/ml) and APRIL (0,01 [0,01-0,62] vs 0,01 [0,01-0,01] ng/ml) levels. Among SLE pts BAFF level correlated with lupus anticoagulant (r=0,88, p,0,05) and ESR (r=0,43, p,0,05); APRIL level correlated with SLEDAI 2K (r=0,55, p,0,01), CRP (r=0,50, p,0,01), antiDNA (r=0,38, p,0,05), creatinine level (r=0,39, p,0,05), current prednisone dose (r=0,55, p,0,01) and CD19 B lymphocytes absolute count (r=0,89, p,0,05). We divided SLE pts on two groups: the 1st- pts with high activity (SLEDAI 2K≥8), the 2nd - pts with low (SLEDAI 2K,8). The patients of 1st group had higher level of APRIL (1,69 [0,01-4,0] vs 0,01 [0,01-0,01] ng/ml, p,0,05) compared to 2nd group and control, there is no difference in BAFF level in these groups.. ...
BAFF and APRIL are innate immune mediators that trigger immunoglobulin G (IgG) and IgA class-switch recombination (CSR) in B cells by engaging the receptor TACI. The mechanism that underlies CSR signaling by TACI remains unknown. Here we found that the cytoplasmic domain of TACI encompasses a conserved motif that bound MyD88, an adaptor that activates transcription factor NF-kappaB signaling pathways via a Toll-interleukin 1 (IL-1) receptor (TIR) domain. TACI lacks a TIR domain, yet triggered CSR via the DNA-editing enzyme AID by activating NF-kappaB through a Toll-like receptor (TLR)-like MyD88-IRAK1-IRAK4-TRAF6-TAK1 pathway. TACI-induced CSR was impaired in mice and humans lacking MyD88 or the kinase IRAK4, which indicates that MyD88 controls a B cell-intrinsic, TIR-independent, TACI-dependent pathway for immunoglobulin diversification. ...
SED021Mu, FTH1; FTHL6; PIG15; PLIF; Ferritin Heavy Chain; Apoferritin; Placenta Immunoregulatory Factor; Proliferation-Inducing Protein 15; Cell proliferation-inducing gene 15 protein | Products for research use only!
Transducer of ErbB-2, 1 (TOB1) is an antiproliferative factor that belongs the tob/btg1 family. TOB1 and TOB2 have the ability to suppress cell growth in cell culture. TOB1 is phosphorylated by ribosomal S6 serine/threonine kinase. It interacts with ErbB-2 and interferes with growth suppression in B cells. TOB1 also inhibits T cell proliferation and the transcription of some cytokines, including interleukin 2 (IL-2). TOB1 is also known as TROB1, TROB, TOB, APRO6, and proliferation-inducing gene 49 (PIG49).. ...
Transducer of ErbB-2, 1 (TOB1) is an antiproliferative factor that belongs the tob/btg1 family. TOB1 and TOB2 have the ability to suppress cell growth in cell culture. TOB1 is phosphorylated by ribosomal S6 serine/threonine kinase. It interacts with ErbB-2 and interferes with growth suppression in B cells. TOB1 also inhibits T cell proliferation and the transcription of some cytokines, including interleukin 2 (IL-2). TOB1 is also known as TROB1, TROB, TOB, APRO6, and proliferation-inducing gene 49 (PIG49).. ...
Anyone who has ever prepared a meal with a process called sous vide, which involves putting ingredients in a plastic pouch and cooking them, raves about the wonderful tastes that result.There is
The cytokine BAFF is produced by a number of cell types, including monocytes, neutrophils, macrophages, dendritic cells, and some subsets of T cells (17). Receptors for BAFF, however, were initially thought to be restricted to more differentiated B-lineage cells. Therefore, the expression of BAFF receptors on transformed B-lineage lymphocytes in CLL was not entirely unexpected. In contrast, based on BAFF-null and BAFF-R-null mutants as well as other studies, it has been generally accepted that precursor B-lineage cells do not express this receptor. Our studies confirm that there is no expression of this receptor in normal bone marrow pre-B cells. Interestingly, Rodig and colleagues (35) also performed FACS on two pre-B ALL samples and reported that these were negative for expression of BAFF-R. Therefore, the prominent expression of the BAFF-R that we detected on both Ph-positive and Ph-negative ALL samples was unanticipated. In fact, all 12 samples that were tested by us, including original ALL ...
BISPECIFIC ANTIBODIES AGAINST CD3 EPSILON AND BCMA FOR USE IN TREATMENT OF DISEASES | BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA | ANTI-CEACAM1 RECOMBINANT ANTIBODIES FOR CANCER THERAPY | METHODS OF CONSTRUCTING AMINO TERMINAL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF | ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF |
Measure human BAFF/BLyS in cell culture supernates, serum, and plasma with our highly sensitive BAFF/BLyS/TNFSF13B Quantikine ELISA Kit.
B lymphocyte stimulator (BLyS) controls the proportion of transitional B cells completing differentiation and the longevity of most primary B cells. These key roles in B cell selection, survival and homeostasis make BLyS and its receptors attractive candidates for targeted B cell therapeutics. Here we have used a neutralizing hamster anti-mouse BLyS antibody to assess how BLyS depletion influences developing and primary B cell subsets, as well as how this treatment impacts primary TD and TI immune responses. Mice treated with 10F4 show rapid and substantial reductions in the transitional, follicular, and marginal zone pools which persist for ~40 days. In contrast, the only bone marrow subset affected is the mature recirculating B cell fraction. Interestingly, splenic B1 cells, but not peritoneal B1 cells, are reduced as well. Following the recovery of serum BLyS levels, peripheral reconstitution occurs gradually, such that normal B cell numbers return by day 70-80. Mice challenged with ...
This finding was the first discovery of the impact of chronic DU exposure on B-cell maturation, and the function of the mature B-cells in recognising antigens and mediating. specific immune responses was thereby affected. The impact of DU on humoral immunity was apparently similar to that of radiation. Exposure to low doses of gamma external irradiation (10 cGy, 1 cGy/min) activated the thymus-dependent humoral immune and enhanced polyclonal B-cells in mice (Sharetskiĭ et al., 2000). It should be clarified that both immunosuppression and immune stimulation are immunotoxic reactions (Gleichmann et al., 1989). Third, long-term exposure to DU led to changes in the cellular immune function in the DU300 group (300 mg/kg), including decreased proliferative ability of ConA-stimulated Inhibitor Library datasheet splenic T cells, suppression of delayed-type hypersensitivity, decrease in the number of CD3+ cells, and decrease in the ratio of CD4+/CD8+ splenic T cells.. In Epacadostat purchase the DU30 ...
Tumour necrosis factor family. Family of cytokines that form homotrimeric or heterotrimeric complexes. TNF mediates mature T-cell receptor-induced apoptosis through the p75 TNF receptor. ...
A Tumor Necrosis Factor Family member that is released by activated Lymphocytes. Soluble lymphotoxin is specific for Tumor Necrosis Factor Receptor Type I; Tumor Necrosis Factor Receptor Type II; and Tumor Necrosis Factor Receptor Superfamily, Member 14. Lymphotoxin-alpha can form a Membrane-bound heterodimer with Lymphotoxin-beta that has specificity for the Lymphotoxin beta Receptor ...
B cell maturation starts in the bone marrow but is completed in the spleen (Hardy et al., 2007). Survival of IgM+ splenic B cells is linked to the antiapoptotic B cell lymphoma 2 (BCL2) family of proteins and their opposing proapoptotic antagonist, BCL2-interacting mediator of cell death (BIM; Enders et al., 2003), and depends on "tonic" signals from surface IgM and IgD B cell antigen receptors transmitted through spleen tyrosine kinase (SYK), Brutons tyrosine kinase (BTK), and phosphatidylinositol 3 kinase (Srinivasan et al., 2009). Starting from the transitional 2 (T2) stage, B cells also depend on survival signals provided by a circulating cytokine, B cell-activating factor (BAFF), engaging the BAFF receptor (BAFFR; Khan, 2009). BCRs and BAFFR signal via pathways that activate transcription factors of the NF-κB family, and these play essential roles in mediating survival of B cells (Siebenlist et al., 2005).. CD74, also called MHC II invariant chain or Ii, is a type 2 transmembrane protein ...
B cell maturation starts in the bone marrow but is completed in the spleen (Hardy et al., 2007). Survival of IgM+ splenic B cells is linked to the antiapoptotic B cell lymphoma 2 (BCL2) family of proteins and their opposing proapoptotic antagonist, BCL2-interacting mediator of cell death (BIM; Enders et al., 2003), and depends on "tonic" signals from surface IgM and IgD B cell antigen receptors transmitted through spleen tyrosine kinase (SYK), Brutons tyrosine kinase (BTK), and phosphatidylinositol 3 kinase (Srinivasan et al., 2009). Starting from the transitional 2 (T2) stage, B cells also depend on survival signals provided by a circulating cytokine, B cell-activating factor (BAFF), engaging the BAFF receptor (BAFFR; Khan, 2009). BCRs and BAFFR signal via pathways that activate transcription factors of the NF-κB family, and these play essential roles in mediating survival of B cells (Siebenlist et al., 2005).. CD74, also called MHC II invariant chain or Ii, is a type 2 transmembrane protein ...
Orai1 antibody (ORAI calcium release-activated calcium modulator 1) for ELISA, ICC/IF, IHC-P, WB. Anti-Orai1 pAb (GTX85057) is tested in Human, Mouse samples. 100% Ab-Assurance.
Име -, Clinique Antiperspirant-Deodorant Roll-On Бранд -, Клиник Предназначение -, Рол он против изпотяване($11 за 60 мл) Текстура -, Флуид Къде? -, В магазините,където се предлага марката Оценка -, 5/6 Може би най-добрият рол-он,който съм ползвала досега (през ръцете ми са минали десетки : скъпи,евтини,натурални,родни,чужбински и т.н.) Клиник не е сред … Continue reading →. ...
The goals of treatment of Wernicke-Korsakoff syndrome are to control symptoms as much as possible and to prevent progression of the disorder.
CD1d-restricted invariant NKT (iNKT) cells boost humoral immunity to T-dependent Ags that are coadministered with the CD1d-binding glycolipid Ag α-galactosylceramide (α-GC). Observations that mice lacking iNKT cells have decaying Ab responses following vaccination have led to the hypothesis that iNKT cells express plasma cell (PC) survival factors that sustain specific Ab titers. Bone marrow chimeric mice in which the entire hematopoietic compartment or iNKT cells selectively lacked BAFF, a proliferation-inducing ligand (APRIL), or both BAFF and APRIL were created and immunized with nitrophenol hapten-conjugated keyhole limpet hemocyanin adsorbed to Imject aluminum hydroxide-containing adjuvant or mixed with α-GC. In comparison with BAFF- or APRIL-sufficient bone marrow chimeras, absence of hematopoietic compartment- and iNKT-derived BAFF and APRIL was associated with rapidly decaying Ab titers and reduced PC numbers. The iNKT cell-derived BAFF or APRIL assumed a greater role in PC survival ...
The IUPHAR/BPS Guide to Pharmacology. OX40 - Tumour necrosis factor (TNF) receptor family. Detailed annotation on the structure, function, physiology, pharmacology and clinical relevance of drug targets.

B-cell maturation antigen - WikipediaB-cell maturation antigen - Wikipedia

B-cell maturation antigen (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a ... Shu HB, Johnson H (Aug 2000). "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1". ... Shu HB, Johnson H (Aug 2000). "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1". ... TNFRSF17 is a cell surface receptor of the TNF receptor superfamily which recognizes B-cell activating factor (BAFF). The ...
more infohttps://en.wikipedia.org/wiki/B-cell_maturation_antigen

What does b-cell maturation antigen mean?What does b-cell maturation antigen mean?

Meaning of b-cell maturation antigen. What does b-cell maturation antigen mean? Information and translations of b-cell ... maturation antigen in the most comprehensive dictionary definitions resource on the web. ... Definition of b-cell maturation antigen in the Definitions.net dictionary. ... What does b-cell maturation antigen mean?. Definitions for b-cell maturation antigen. Here are all the possible meanings and ...
more infohttps://www.definitions.net/definition/b-cell%20maturation%20antigen

JCI -
B cell maturation antigen-specific CAR T cells are clinically active in multiple myelomaJCI - B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma

CAR T cells are a promising therapy for hematologic malignancies. B cell maturation antigen (BCMA) is a rational target in ... B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. ... B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. ... 0.26). *Subject 15 had no detectable MM cells at D28. #Subject 03 had no detectable MM cells at D45 (D28 not done) and too few ...
more infohttps://www.jci.org/articles/view/126397/figure/5

JCI -
B cell maturation antigen-specific CAR T cells are clinically active in multiple myelomaJCI - B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma

CAR T cells are a promising therapy for hematologic malignancies. B cell maturation antigen (BCMA) is a rational target in ... B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. ... B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. ... Responses and CART-BCMA expansion were associated with CD4/CD8 T cell ratio and frequency of CD45RO-CD27+CD8+ T cells in the ...
more infohttps://www.jci.org/articles/view/126397/sd/1

Significant Number of B-cell Maturation Antigen (BCMA) Targeted Therapies in Pipeline is Expected to Boost Market GrowthSignificant Number of B-cell Maturation Antigen (BCMA) Targeted Therapies in Pipeline is Expected to Boost Market Growth

Beta cell maturation antigen antibody drug conjugate. Phase 1. bluebird bio, Inc. and Celgene Corporation. Anti-BCMA CAR-T cell ... B-cell maturation antigen (BCMA) has emerged as a very selective antigen to be targeted for the treatment of multiple myeloma. ... Significant Number of B-cell Maturation Antigen (BCMA) Targeted Therapies in Pipeline is Expected to Boost Market Growth. Email ... the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market (By product type: CAR-T cell, bispecific antibodies, and ...
more infohttps://www.globenewswire.com/news-release/2017/10/26/1154405/0/en/Significant-Number-of-B-cell-Maturation-Antigen-BCMA-Targeted-Therapies-in-Pipeline-is-Expected-to-Boost-Market-Growth.html

CAR T Cells Targeting B-Cell Maturation Antigen in Poor-Prognosis Relapsed Multiple Myeloma - The ASCO PostCAR T Cells Targeting B-Cell Maturation Antigen in Poor-Prognosis Relapsed Multiple Myeloma - The ASCO Post

CAR T Cells Targeting B-Cell Maturation Antigen in Poor-Prognosis Relapsed Multiple Myeloma. By Matthew Stenger. Posted: 6/27/ ... autologous T cells targeting B-cell maturation antigen (BCMA) produced responses in patients with poor-prognosis relapsed ... At 6 to 9 days postinfusion, CAR-BCMA T cells in the blood were predominantly highly differentiated CD8-positive T cells. ... In a first-in-human study reported in the Journal of Clinical Oncology, Brudno et al found that chimeric antigen receptor (CAR ...
more infohttp://www.ascopost.com/News/58996

Baff Binds to the Tumor Necrosis Factor Receptor-Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the...Baff Binds to the Tumor Necrosis Factor Receptor-Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the...

... binds B cells and enhances B cell receptor-triggered proliferation. We find that B cell maturation antigen (BCMA), a predicted ... B cell maturation antigen (BCMA) was first identified as part of a translocation event in a malignant T cell lymphoma patient ( ... Baff Binds to the Tumor Necrosis Factor Receptor-Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the ... Baff Binds to the Tumor Necrosis Factor Receptor-Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the ...
more infohttp://jem.rupress.org/content/192/1/129?ijkey=e53cdc8d49b0a4943220ccf5e9449dd07bac9a0b&keytype2=tf_ipsecsha

2018-2025 B-Cell Maturation Antigen (BCMA) Targeted Therapies Report on Global and United States Market, Status and Forecast,...2018-2025 B-Cell Maturation Antigen (BCMA) Targeted Therapies Report on Global and United States Market, Status and Forecast,...

Summary This report studies the B-Cell Maturation Antigen(BCMA)... ... 120 Pages Report] Check for Discount on 2018-2025 B-Cell Maturation Antigen (BCMA) Targeted Therapies Report on Global and ... 2.3 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Segment by Type. 2.3.1 Global B-Cell Maturation Antigen( ... 5.5.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Rate. 5.5.2 Global B-Cell Maturation Antigen(BCMA ...
more infohttps://www.reportsnreports.com/reports/1338115-2018-2025-b-cell-maturation-antigen-bcma-targeted-therapies-report-on-global-and-united-states-market-status-and-forecast-by-players-types-and-applications.html

Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric...Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric...

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM) ... Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) ... DNA, RNA & Cells. *Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen ( ... and B-cell maturation antigen (BCMA)-specific CAR-T compounds, and T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL ...
more infohttps://pipelinereview.com/index.php/2019010970290/DNA-RNA-and-Cells/Cellular-Biomedicine-Group-Initiates-Patient-Recruitment-for-Clinical-Trial-in-B-Cell-Maturation-Antigen-Anti-BCMA-Chimeric-Antigen-Receptor-T-Cell-CAR-T-Therapy-Target.html

B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord...B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord...

... and B-cell-activating factor (BAFF), and one receptor, B-cell maturation antigen (BMCA) involved in B cell development, ... To our knowledge, this is the first report that peripheral blood mononuclear cells produce increased levels of BAFF and APRIL ... This finding provides evidence of systemic regulation of SCI-autoimmunity via APRIL and BAFF mediated activation of B cells ... Recent groundbreaking studies in rodents indicate that B cells are responsible for SCI-induced autoimmunity. This novel ...
more infohttps://www.semanticscholar.org/paper/B-cell-maturation-antigen%2C-a-proliferation-inducing-Saltzman-Battaglino/48400ebb149b18a4f2266323edcfb4a65da4772d

CAR T-celtherapie met het B-cell maturation antigen (BCMA) geeft alsnog complete remissies bij meer dan de helft van de 18...CAR T-celtherapie met het B-cell maturation antigen (BCMA) geeft alsnog complete remissies bij meer dan de helft van de 18...

CAR T-celtherapie met een B-cell maturation antigen (BCMA) geeft alsnog complete remissies bij de helft van de 18 geselecteerde ... we have designed a second-generation CAR construct targeting B cell maturation antigen (BCMA) to redirect T cells to MM cells. ... CAR T-celtherapie met het B-cell maturation antigen (BCMA) geeft alsnog complete remissies bij meer dan de helft van de 18 ... Nieuwe vervolgstudie op onderstaande studie bewijst dat CAR-T cel therapie met bb2121 gericht op het B-cell maturation antigen ...
more infohttps://kanker-actueel.nl/car-t-celtherapie-met-het-b-cell-maturation-antigen-bcma-geeft-alsnog-complete-remissies-bij-meer-dan-de-helft-van-de-18-geselecteerde-zwaar-voorbehandelde-patienten-met-vergevorderde-multiple-myeloma-kahler.html

Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market 2018Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market 2018

... - Credit Suisse Securities, Eureka Therapeutics, Deerfield ... The B-Cell Maturation Antigen Targeted Therapies report begins with the overview of B-Cell Maturation Antigen Targeted ... The B-Cell Maturation Antigen Targeted Therapies research report covers B-Cell Maturation Antigen Targeted Therapies market in ... Section 1. B-Cell Maturation Antigen Targeted Therapies Market Overview.. Section 2. Global B-Cell Maturation Antigen Targeted ...
more infohttps://askthereporter24.com/global-b-cell-maturation-antigenbcma-targeted-therapies-market-2018/

Serum B-Cell Maturation Antigen: A Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients - Institute for Myeloma &...Serum B-Cell Maturation Antigen: A Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients - Institute for Myeloma &...

B-cell maturation antigen is expressed on plasma cells. In this study, we have identified serum B-call maturation antigen as a ... patients with multiple myeloma showed elevated serum B-cell maturation antigen levels (P < 0.0001). Serum B-cell maturation ... Among patients with non secretory disease, serum B-cell maturation antigen levels correlated with bone marrow plasma cell ... Serum B-Cell Maturation Antigen: A Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients. Michael Ghermezi, Mingjie ...
more infohttps://www.imbcr.org/serum-b-cell-maturation-antigen-novel-biomarker-predict-outcomes-multiple-myeloma-patients/

JCI -
B cell maturation antigen-specific CAR T cells are clinically active in multiple myelomaJCI - B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma

CAR T cells are a promising therapy for hematologic malignancies. B cell maturation antigen (BCMA) is a rational target in ... B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. ... B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. ... Responses and CART-BCMA expansion were associated with CD4/CD8 T cell ratio and frequency of CD45RO-CD27+CD8+ T cells in the ...
more infohttps://zjtyuety.com.insight.mobile.jci.org/articles/view/126397/figure/2

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma - CareAcrossStudy of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma - CareAcross

To test the safety of giving anti-B-Cell Maturation Antigen T cells to people with multiple myeloma.

Eligibility:
< ... T cells are removed. The rest of the blood is returned through a needle in the other arm.

- The cells will be changed ... They will get the T cells through the IV in 1 infusion.

- After this, participants will stay in the hospital for at ... One cancer therapy involves removing a person s T cells, changing them in a lab, and then returning them to the person. ...
more infohttps://www.careacross.com/clinical-trials/trial/NCT02215967

Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high...Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high...

Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high ... Dendritic cells (DCs) are promising antigen presenting cells for cancer treatment. Previously, we showed that the combination ... Furthermore, the CTLs proved to kill tumour cells expressing endogenous tumour antigen in vitro. Therefore, MPLA/IFNgamma DCs ... amounts of induced CTLs are functional as they produce IFNgamma and lyse target cells and this cytolytic activity is antigen ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/20336295?dopt=Abstract

Survivin Essential for the Maturation of Antigen Presenting Cells in Rheumatoid Arthritis Patients - The RheumatologistSurvivin Essential for the Maturation of Antigen Presenting Cells in Rheumatoid Arthritis Patients - The Rheumatologist

Survivin Essential for the Maturation of Antigen Presenting Cells in Rheumatoid Arthritis Patients. January 2, 2013. • By Lara ... Survivin Essential for the Maturation of Antigen Presenting Cells in Rheumatoid Arthritis Patients ... of survival for bone marrow and spleen hematopoietic cells as they mature and differentiate into antigen presenting cells. ... Studies also have demonstrated that peripheral dendritic cells mature in the spleen and do so in a process that is dependent on ...
more infohttps://www.the-rheumatologist.org/article/survivin-essential-for-the-maturation-of-antigen-presenting-cells-in-rheumatoid-arthritis-patients/

Interaction of Mouse Dendritic Cells and Malaria-Infected Erythrocytes: Uptake, Maturation, and Antigen Presentation | The...Interaction of Mouse Dendritic Cells and Malaria-Infected Erythrocytes: Uptake, Maturation, and Antigen Presentation | The...

Interaction of Mouse Dendritic Cells and Malaria-Infected Erythrocytes: Uptake, Maturation, and Antigen Presentation. Rebecca ... Red cells were lysed with NH4Cl lysing buffer. Cells were plated in 6-well plates at a concentration of 2.5 × 105 cells/ml in ... Interaction of Mouse Dendritic Cells and Malaria-Infected Erythrocytes: Uptake, Maturation, and Antigen Presentation ... In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. ...
more infohttp://www.jimmunol.org/content/176/1/441.long

Thymic maturation determines γδ T cell function, but not their antigen specificitiesThymic maturation determines γδ T cell function, but not their antigen specificities

... antigen recognition drives effector function development, where antigen naïve cells make IL-17 and antigen experienced cells ... Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced ... cells with prior antigen exposure produce IFNγ while cells that develop in the absence of ligand make IL-17. γδ T cells are the ... Thymic maturation determines γδ T cell function, but not their antigen specificities. Kirk D. C. Jensen1,2 and Yueh-hsiu Chien1 ...
more infohttp://pubmedcentralcanada.ca/pmcc/articles/PMC2697822/

Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells | Research - Institut PasteurSec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells | Research - Institut Pasteur

Cell 2011 Dec;147(6):1355-68. Antigen (Ag) crosspresentation by dendritic cells (DCs) involves the presentation of internalized ... Example: +cell +stem * Tip 3. You can use + and - symbols to force inclusion or exclusion of specific words.. Example: +cell - ... Published in Cell - 01 Dec 2011. Cebrian I, Visentin G, Blanchard N, Jouve M, Bobard A, Moita C, Enninga J, Moita LF, Amigorena ... Ags on MHC class I molecules to initiate CD8+ T cell-mediated immunity in response to certain pathogens and tumor cells. Here, ...
more infohttps://research.pasteur.fr/en/publication/sec22b-regulates-phagosomal-maturation-and-antigen-crosspresentation-by-dendritic-cells/

Retractde: Intracellular NOD2 activation promotes maturation and antigen-presenting functions of dendritic cells exposed to...Retractde: Intracellular NOD2 activation promotes maturation and antigen-presenting functions of dendritic cells exposed to...

Intracellular NOD2 activation promotes maturation and antigen-presenting functions of dendritic cells exposed to Porphyromonas ... Muramyl dipeptide, P. gingivalis-LPS, Dendritic cells, Maturation, Antigen-presenting. Introduction. Dendritic Cells (DCs) are ... Retractde: Intracellular NOD2 activation promotes maturation and antigen-presenting functions of dendritic cells exposed to ... Cell culture. Total bone marrow cells were freshly isolated from tibias, femurs and humerus of the rats. Cells were cultured in ...
more infohttp://www.alliedacademies.org/articles/intracellular-nod2-activation-promotes-maturation-and-antigenpresenting-functions-of-dendritic-cells-exposed-to-porphyromonas-ging-9757.html

B-cell maturation in chimaeric mice deficient for the heat stable antigen (HSA/mouse CD24).  - Zurich Open Repository and...B-cell maturation in chimaeric mice deficient for the heat stable antigen (HSA/mouse CD24). - Zurich Open Repository and...

B-cell maturation in chimaeric mice deficient for the heat stable antigen (HSA/mouse CD24). ... B-cell maturation in chimaeric mice deficient for the heat stable antigen (HSA/mouse CD24). Transgenic Research, 4(3):173-183. ... These mice contain normal numbers of peripheral B-cells and normal serum IgM and IgG titres of ES cell-derived allotype, ... These mice contain normal numbers of peripheral B-cells and normal serum IgM and IgG titres of ES cell-derived allotype, ...
more infohttp://www.zora.uzh.ch/id/eprint/1257/

Effective functional maturation of invariant natural killer T cells is constrained by negative selection and T-cell antigen...Effective functional maturation of invariant natural killer T cells is constrained by negative selection and T-cell antigen...

Effective functional maturation of invariant natural killer T cells is constrained by negative selection and T-cell antigen ... Effective functional maturation of invariant natural killer T cells is constrained by negative selection and T-cell antigen ... Invariant NK T cells (iNKT) cells are a conserved population of innate-like T cells that recognize lipid antigens complexed to ... A semi-invariant Vα10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen- ...
more infohttps://www.pnas.org/content/111/1/E119

ASTRO Annual MeetingASTRO Annual Meeting

T cells genetically modified to express a chimeric antigen receptor targeting B-cell maturation antigens demonstrated strong… ... Anti-B-cell maturation antigen CAR T cells show promise for advanced multiple myeloma. December 5, 2015. ORLANDO, Fla. - ... Variants in bone and fat differentiation genes within mesenchymal stem cells appeared associated with development of… ...
more infohttps://www.healio.com/hematology-oncology/meeting-news/astro-meeting?startItem=80

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma - Full Text View - ClinicalTrials...BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma - Full Text View - ClinicalTrials...

A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells ... B-cell Maturation Antigen (BCMA). Targeted EGFRt/BCMA-41BBz. Chimeric antigen receptor (CAR). Lenalidomide. 17-025. ... Experimental: BCMA Targeted CAR T Cells with or without Lenalidomide Biological: EGFRt/BCMA-41BBz CAR T cell Modified T cell ... 7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort ...
more infohttps://clinicaltrials.gov/ct2/show/NCT03070327
  • Moreover, culturing splenic cells in the presence of BAFF increased survival of a percentage of the B cells. (rupress.org)
  • These results are consistent with a role for BAFF in maintaining homeostasis of the B cell population. (rupress.org)
  • Transgenic mice overexpressing BAFF have a greatly elevated number of mature B cells and an increased number of effector T cells in their spleen and mesenteric lymph nodes ( 6 ). (rupress.org)
  • However, splenic B cells from transgenic or control mice were found to proliferate at the same rate ( 6 ), suggesting that BAFF, in addition to its ability to costimulate B cell proliferation in vitro, may have alternative functions. (rupress.org)
  • This may be due to a B cell survival function of BAFF. (rupress.org)
  • Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments. (semanticscholar.org)
  • B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. (nih.gov)
  • Title: Neutrophils contribute to excess serum BAFF levels and promote CD4+ T cell and B cell responses in lupus-prone mice. (nih.gov)
  • Now based at Monash, her group continues to explore new functions of BAFF, B cell subsets, and innate immunity in tolerance, autoimmunity and cancer. (nature.com)
  • However, in 2011, a therapeutic monoclonal antibody that neutralizes the cytokine TNF ligand superfamily member 13B (also known as B-cell-activating factor of the TNF family [BAFF]), belimumab, became the first targeted therapy for SLE to have efficacy in a randomized clinical trial. (nature.com)
  • In this article, therefore, we review results suggesting that neutralizing BAFF can have effects on the immune system other than depletion of B cells. (nature.com)
  • Patients must have measurable MM defined as a serum M-protein greater than or equal to 1 g/dL or a urine M-protein greater than or equal to 200 mg/24 hours or an involved serum free light chain (FLC) level greater than or equal to 10 mg/dL (provided FLC ratio is abnormal) or a biopsy-proven plasmacytoma or greater than 30% bone marrow plasma cells. (careacross.com)
  • Recently, the expression of an immunoglobulin-like transmembrane protein, encoded by Skint1 (selection and upkeep of intraepithelial T cells 1) , on fetal thymic stromal cells was identified as necessary for the positive selection of the DETCs [ 8 ]. (pubmedcentralcanada.ca)
  • A Phase IIb trial in China for Rejoin® autologous Human Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial in China for AlloJoin™ (CBMG's "Off-the-Shelf" haMPC) for the treatment of KOA are ongoing. (pipelinereview.com)
  • The uptake of pRBCs by splenic CD11c + DCs was significantly enhanced after infection in vivo and was associated with the induction of DC maturation, IL-12 production, and stimulation of CD4 + T cell proliferation and IFN-γ production. (jimmunol.org)
  • CCK8 was used to assess CD4+ T cells proliferation after co-cultured with DCs stimulated by MDP and P. gingivalis -LPS, respectively or in synergism and ELISA was used to detect IL-2, IFN-γ, IL-10 and IL-13 secreted by these T cells. (alliedacademies.org)
  • MDP could promote CD4+T cells proliferation primed by DCs exposed to P. gingivalis -LPS and elevate the ability of DCs exposed to P. gingivalis -LPS to prime Th0 cells to Th2 cells. (alliedacademies.org)
  • The high amounts of induced CTLs are functional as they produce IFNgamma and lyse target cells and this cytolytic activity is antigen specific and HLA restricted. (nih.gov)
  • Although several cytokines, such as IL-12 in synergy with IL-15 or IL-18, may result in Th1 cell development ( 3 , 4 ), IFN-γ is the central effector cytokine mediating protective immunity to blood-stage malaria infection ( 5 ). (jimmunol.org)
  • The ability of MDP to promote DCs secreting cytokines was far below P. gingivalis- LPS but MDP could promote the functions of Th2 cell-promoting DCs induced by P. gingivalis -LPS. (alliedacademies.org)
  • Priming DCs with microbial compounds up-regulates the expression of costimulatory molecules and the production of proinflammatory cytokines, which drives T-helper (Th) cells to differentiate to Th1 or Th2 cells [ 4 ]. (alliedacademies.org)
  • Recent groundbreaking studies in rodents indicate that B cells are responsible for SCI-induced autoimmunity. (semanticscholar.org)
  • Dr Fabien B. Vincent is a rheumatologist, specialized in autoimmunity, with broad experience of B cell immunology, molecular immunology and the genetic bases of disease. (nature.com)
  • Systemic lupus erythematosus (SLE) is characterized by multisystem immune-mediated injury in the setting of autoimmunity to nuclear antigens. (nature.com)
  • TNFRSF17 has been shown to interact with the B-cell activating factor TNFSF13B. (wikipedia.org)
  • It possess co-immunoprecipitation property with a master transcription factor (IRF-4) that are mediated for myeloma cell survival. (globenewswire.com)
  • Finally, a third potential mode of operation is through the delivery of toxic payloads (chemical or radioactive) directly to tumor cells (McCombs and Owen 2015). (deepdyve.com)
  • The first group, the invariant γδ T cells, are generated from the first two waves of T cells in the fetal thymus and later found in either the epidermis of the skin, or the epithelium of the reproductive tract. (pubmedcentralcanada.ca)
  • In general, it is believed that these invariant γδ T cells recognize host antigens and play a role in epithelial cell maintenance. (pubmedcentralcanada.ca)
  • In the absence of proper Skint1 expression, the epidermal layer lacks the invariant Vδ1+Vγ5+ DETCs (iDETCs) found in normal mice and is instead populated by γδ T cells that express diverse TCR V genes. (pubmedcentralcanada.ca)
  • We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. (pipelinereview.com)
  • Here, we extended these observations by showing that the DCs generated with the clinical grade maturation cocktail of MPLA/IFNgamma induce superior tumour antigen-specific CD8(+) CTL responses compared to the cytokine cocktail matured DCs that are currently used in the clinic. (nih.gov)
  • The purpose of this phase I clinical trial is to test the safety of these CAR T cells in patients with myeloma. (clinicaltrials.gov)
  • These results suggest that DCs selectively phagocytose pRBCs and present pRBC-derived Ags to CD4 + T cells, thereby promoting development of protective Th1-dependent immune responses to blood-stage malaria infection. (jimmunol.org)
  • Immune effector mechanisms that mediate control of parasitemia involve macrophages, NK cells, CD4 + T cells, and IFN-γ production, while B cells and Th1-dependent Ab responses are required for elimination and resolution of the chronic stage of infection (reviewed in Ref. 2 ). (jimmunol.org)
  • This interaction can stimulate a variety of biological responses, depending on the cell type analysed. (biochemj.org)
  • One cancer therapy involves removing a person s T cells, changing them in a lab, and then returning them to the person. (careacross.com)
  • These results highlight the importance of adaptive type 1 immune mechanisms for host resistance to blood-stage malaria and the need to identify critical components of the innate immune response that promote development of IFN-γ-producing CD4 + Th1 cells. (jimmunol.org)
  • Early interactions between blood-stage parasites and cells of the innate immune system are thought to be important in shaping the adaptive immune response to blood-stage malaria. (jimmunol.org)
  • γδ T cells contribute uniquely to host immune defense, but how they do so remains unclear. (pubmedcentralcanada.ca)
  • These advances warrant a fresh look at how γδ T cells may function in the immune system. (pubmedcentralcanada.ca)
  • Promotes B-cell survival and plays a role in the regulation of humoral immunity. (genecards.org)